Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia(R) and Xgeva(R)

BUDAPEST, Hungary and LONDON, Dec. 9, 2021 -- (Healthcare Sales & Marketing Network) -- Gedeon Richter Plc. ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement ... Biopharmaceuticals, Generics, Licensing Hikma Pharmaceuticals, Gedeon Richter, denosumab, Prolia , Xgeva
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news